Difficulty: Medium
Average Score: 63%
Practice
Familial chylomicronemia (type I) is caused by deficiency in lipoprotein lipase activity. This consideration is:
Correct answer
A
Rationale
In the context of Safety Pharmacology across the lifespan, understanding familial chylomicronemia (type I) and its association with lipoprotein lipase activity is crucial for healthcare professionals. The correct answer, A) TRUE, is supported by the fact that familial chylomicronemia, characterized by high levels of chylomicrons due to lipoprotein lipase deficiency, leads to severe hypertriglyceridemia and associated risks like pancreatitis.
Option B) FALSE is incorrect because familial chylomicronemia is indeed caused by lipoprotein lipase deficiency, as indicated by clinical and genetic studies. Option C) All of the above and Option D) None of the above are also incorrect as they do not accurately reflect the specific relationship between lipoprotein lipase deficiency and familial chylomicronemia.
Educationally, this question highlights the importance of understanding genetic conditions that affect lipid metabolism, emphasizing the role of lipoprotein lipase in lipid breakdown and the implications of its deficiency. This knowledge is essential for healthcare professionals to provide appropriate care and guidance to individuals with familial chylomicronemia, especially in pharmacological interventions and dietary management.
Option B) FALSE is incorrect because familial chylomicronemia is indeed caused by lipoprotein lipase deficiency, as indicated by clinical and genetic studies. Option C) All of the above and Option D) None of the above are also incorrect as they do not accurately reflect the specific relationship between lipoprotein lipase deficiency and familial chylomicronemia.
Educationally, this question highlights the importance of understanding genetic conditions that affect lipid metabolism, emphasizing the role of lipoprotein lipase in lipid breakdown and the implications of its deficiency. This knowledge is essential for healthcare professionals to provide appropriate care and guidance to individuals with familial chylomicronemia, especially in pharmacological interventions and dietary management.